×
Effect of hydroxychloroquine on the cardiac ventricular repolarization - a randomized c...
https://doi.org/10.1111/bcp.15013
British Journal of Clinical Pharmacology; Eveleens Maarse BC, Graff C et. al.

Jul 31st, 2021 - Hydroxychloroquine has been suggested as possible treatment for Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-CoV-2). Studies reported an increased risk of QTcF-prolongation after treatment with hydroxychloroquine. The aim of this study was to analyze the concentration-dependent effects of hydroxychloroquine on the ventricular repolarization, including QTcF-duration and T-wave morpholog...

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19.
https://doi.org/10.1183/13993003.02002-2021
The European Respiratory Journal; Xu J, Cao B

Jul 31st, 2021 - Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19.|2021|Xu J,Cao B,|

Trends in COVID-19 cases and clinical management in Veterans Health Administration medi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321215
PloS One; Aboumrad M, Shiner B et. al.

Jul 30th, 2021 - We explored longitudinal trends in sociodemographic characteristics, reported symptoms, laboratory findings, pharmacological and non-pharmacological treatment, comorbidities, and 30-day in-hospital mortality among hospitalized patients with coronavirus disease 2019 (COVID-19). This retrospective cohort study included patients diagnosed with COVID-19 in the United States Veterans Health Administ...

COVID-19: Are Experimental Drugs Cure or Ill?
https://doi.org/10.2174/1574886316666210727150127
Current Drug Safety; Karahalil B, Elkama A

Jul 29th, 2021 - Coronavirus disease 2019 (COVID-19) is a new strain of coronavirus. It is characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has quickly influenced all over the world since it spreads easily. Common symptoms are fever, cough, difficulty in breathing and muscle aches. Despite the urgent need to find an effective antiviral treatment, already available agents are bei...

Hydroxychloroquine and Azithromycin Combination in The Management of COVID-19 Infection...
https://doi.org/10.2174/1574886316666210727152609
Current Drug Safety; Warda AEA, Tammam M et. al.

Jul 29th, 2021 - The treatment of COVID-19 disease remains a dilemma so far because there is no approved therapy for it. This study aimed to evaluate the use of hydroxychloroquine and azithromycin combination in treatment. This study was carried out to determine the safety and effectiveness of hydroxychloroquine and azithromycin combination in COVID 19 patients. This study included 90 adult COVID 19 patients. T...

Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review.
https://doi.org/10.2174/1871526521666210726150435
Infectious Disorders Drug Targets; Mehraeen E, Najafi Z et. al.

Jul 28th, 2021 - COVID-19 is the third rising epidemic in the 21st century that quickly turned into a worldwide pandemic. Many clinical studies have been achieved to investigate treatments to confrontation of COVID-19. Therefore, we conducted a systematic reviewto describe the recent treatment strategies to treat COVID-19 patients. A systematic search was performed in the databases of PubMed, Scopus, Embase, Sc...

Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254655
Journal of Immunology Research; Bitaraf E, Ahmadi SAY et. al.

Jul 27th, 2021 - Regulation of the immune system is critical for fighting against viral infections. Both suppression and hyperactivity of the immune system result in failure of treatment. The present study was designed to show the effects of immune system-related medications on mortality and length of stay (LOS) in a cohort of Iranian patients with coronavirus disease 2019 (COVID-19). A data mining study was pe...

G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydrox...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299738
The Pharmacogenomics Journal; da Rocha JEB, Othman H et. al.

Jul 25th, 2021 - Chloroquine/hydroxychloroquine have been proposed as potential treatments for COVID-19. These drugs have warning labels for use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Analysis of whole genome sequence data of 458 individuals from sub-Saharan Africa showed significant G6PD variation across the continent. We identified nine variants, of which four are potentially...

Variation in COVID-19 characteristics, treatment and outcomes in Michigan: an observati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313307
BMJ Open; Chopra V, Flanders SA et. al.

Jul 25th, 2021 - To describe patient characteristics, symptoms, patterns of care and outcomes for patients hospitalised with COVID-19 in Michigan. Multicentre retrospective cohort study. 32 acute care hospitals in the state of Michigan. Patients discharged (16 March-11 May 2020) with suspected or confirmed COVID-19 were identified. Trained abstractors collected demographic information on all patients and detail...

Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells.
https://doi.org/10.1016/j.dnarep.2021.103180
DNA Repair; Besaratinia A, Caliri AW et. al.

Jul 24th, 2021 - Since the early stages of the pandemic, hydroxychloroquine (HCQ), a widely used drug with good safety profile in clinic, has come to the forefront of research on drug repurposing for COVID-19 treatment/prevention. Despite the decades-long use of HCQ in the treatment of diseases, such as malaria and autoimmune disorders, the exact mechanisms of action of this drug are only beginning to be unders...

A Retrospective Analysis of the Impact of the Coronavirus Disease 2019 Pandemic on Heal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006193
Journal of Emergency Nursing; Öztürk B, Öztürk S et. al.

Jul 24th, 2021 - Several vaccines have been developed and approved for use against severe acute respiratory syndrome coronavirus-2; however, the use of personal protective equipment remains important owing to the lack of effective specific treatment and whole community immunity. Hydroxychloroquine sulfate was a treatment option in the early days of the pandemic; however, it was subsequently removed owing to a l...

QTc interval prolongation, inflammation, and mortality in patients with COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295006
Journal of Interventional Cardiac Electrophysiology : an ... Gulletta S, Della Bella P et. al.

Jul 23rd, 2021 - Systemic inflammation has been associated with corrected QT (QTc) interval prolongation. The role of inflammation on QTc prolongation in COVID-19 patients was investigated. Patients with a laboratory-confirmed SARS-CoV-2 infection admitted to IRCCS San Raffaele Scientific Institute (Milan, Italy) between March 14, 2020, and March 30, 2020 were included. QTc-I was defined as the QTc interval by ...

A dossier on COVID-19 chronicle.
https://doi.org/10.1515/jbcpp-2020-0511
Journal of Basic and Clinical Physiology and Pharmacology; Rufaida , Mahmood T et. al.

Jul 20th, 2021 - The dissemination of the 2019 novel coronavirus (2019-nCoV) is presenting the planet with a new health emergency response or threat to health. The virus emerged in bats and was disseminated to humans in December 2019 via still unknown intermediate species in Wuhan, China. It is disseminated by inhalation or breaks out with infected droplets and the incubation period is between 2 and 14 days. Th...

Open-source institutional guideline recommendations during the COVID-19 pandemic.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454286
American Journal of Health-system Pharmacy : AJHP : Offic... Collins CD, Huang J et. al.

Jul 20th, 2021 - The global coronavirus disease 2019 (COVID-19) pandemic and the search for ways in which to provide the best available care have created unprecedented times in terms of rapidly evolving reports of available treatment options. The primary objective of our analysis was to categorize online, open-source guidance to determine how US institutions approached their recommendations for management of pa...

Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270750
International Immunopharmacology; Alavi Darazam I, Shokouhi S et. al.

Jul 18th, 2021 - The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy. The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moderate-severe hospitalized patients with confirmed SARS-Cov-2 infection were randomly segregated into intervention and control groups. The intervention group were treated ...

Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273040
Travel Medicine and Infectious Disease; Chivese T, Musa OAH et. al.

Jul 16th, 2021 - To synthesize findings from systematic reviews and meta-analyses on the efficacy and safety of chloroquine (CQ) and hydroxychloroquine (HCQ) with or without Azithromycin for treating COVID-19, and to update the evidence using a meta-analysis. A comprehensive search was carried out in electronic databases for systematic reviews, meta-analyses and experimental studies which investigated the effic...

Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284736
Medicine Ding J, Liu W et. al.

Jul 15th, 2021 - Corrected QT (QTc) interval prolongation has been associated with poor patient prognosis. In this study, we assessed the effects of different drugs and cardiac injury on QTc interval prolongation in patients with coronavirus disease 2019 (COVID-19).The study cohort consisted of 395 confirmed COVID-19 cases from the Wuhan Union Hospital West Campus. All hospitalized patients were treated with ch...

Ivermectin for COVID: How Do We Know What to Believe?
https://www.medscape.com/viewarticle/954681

Jul 14th, 2021 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. This transcript has been edited for clarity. Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson of the Yale School of Medicine. This week, it's time we talk about ivermectin. Since the first days of the COVID-19 pandemic, various existing drugs have been tou...

Cationic Compounds with SARS-CoV-2 Antiviral Activity and their Interaction with OCT/MA...
https://doi.org/10.1124/jpet.121.000619
The Journal of Pharmacology and Experimental Therapeutics; Martinez Guerrero LJ, Zhang X et. al.

Jul 14th, 2021 - In the wake of the COVID-19 pandemic, drug repurposing has been highlighted for rapid introduction of therapeutics. Proposed drugs with activity against SARS-CoV-2 include compounds with positive charges at physiological pH, making them potential targets for the organic cation (OC) secretory transporters of kidney and liver, i.e., the basolateral Organic Cation Transporters, OCT1 and OCT2; and ...

Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and...
https://doi.org/10.1002/jmv.27195
Journal of Medical Virology; Kalantari S, Fard SR et. al.

Jul 14th, 2021 - The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients based on clinical and laboratory parameters. We prospectively evaluated the clinical and laboratory outcomes of 62 moderate to severe COVID-19 patients during a 10-day treatment plan. Patients were r...